预约演示
更新于：2025-02-14
Mirabegron
米拉贝隆
更新于：2025-02-14
概要
基本信息
药物类型 小分子化药 |
别名 Betmiga PR、Mirabegron (USAN/JAN)、Myrbetriq Granules + [8] |
作用机制 GP IIb/IIIa拮抗剂(糖蛋白 IIb/IIIa拮抗剂) |
治疗领域 |
最高研发阶段批准上市 |
首次获批日期 日本 (2011-07-01), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C21H24N4O2S |
InChIKeyPBAPPPCECJKMCM-IBGZPJMESA-N |
CAS号223673-61-8 |
关联
239
项与 米拉贝隆 相关的临床试验NCT05713799
Phase II Trial of the Combination of Alpha-lipoic Acid and Mirabegron in Women and in Men With Obesity
NCT06791460
Pegylated Liposomal Doxorubicin Plus Adebrelimab with or Without Mirabegron in Relapsed Ovarian Cancer: a Randomized, Controlled, Open-label Trial
NCT06803030
A Comparative Study on the Efficacy of Tamsulosin, Solifenacin and Mirabegron in Alleviating Ureteral Stent-related Symptoms: a Randomized Controlled Trial
100 项与 米拉贝隆 相关的临床结果
登录后查看更多信息
100 项与 米拉贝隆 相关的转化医学
登录后查看更多信息
100 项与 米拉贝隆 相关的专利（医药）
登录后查看更多信息
1,112
项与 米拉贝隆 相关的文献（医药）2025-02-01NEUROUROLOGY AND URODYNAMICS
Trends in Overactive Bladder Therapy: Associations Between Clinical Care Pathways, Practice Guidelines, and Therapy Utilization Patterns
Article
作者: Enemchukwu, Ekene A. ; S. Burton, Claire ; Syan, Raveen ; Gunamany, Susanna ; Sinclair, Shada ; Zhang, Chiyuan A. ; Mohamud, Hodan
ABSTRACT:
Introduction:
Overactive bladder (OAB) is a chronic condition with significant financial and health‐related consequences. Guidelines and treatment pathways were created to optimize care and provide a clinical framework for diagnosing and managing OAB. However, the impact of these efforts and patterns of medical treatment for OAB are poorly understood. Therefore, we sought to evaluate overall trends in therapy utilization before and after the 2014 American Urological Association (AUA)/Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU) OAB guideline amendment and publication of the OAB clinical care pathway in 2016.
Methods:
In this retrospective cohort study, we analyzed data from Optum, a national administrative health and pharmacy claims database, between 2013 and 2018. All adult patients diagnosed with idiopathic OAB were identified by the International Classification of Diseases 9th and 10th Revision codes. Oral OAB therapies were identified using National Drug Codes, while third‐line therapy procedures, onabotulinumtoxinA (BTX), sacral neuromodulation (SNM), and percutaneous tibial nerve stimulation (PTNS), were identified using Current Procedural Terminology (CPT) codes. The study's primary outcome was the annual number of OAB prescriptions filled by pharmacotherapy class and the number of minimally invasive therapies performed during the study period. The secondary outcome was the association between OAB therapy utilization and various clinical and sociodemographic factors. Patterns of care were analyzed from 2013 to 2018, and initial treatment with each therapy was collected, excluding repeat procedures from the analysis.
Results:
1 825 782 patients were included in the study. The mean age was 61.1 ± 16.7 years, and 1 071 420 patients were female (58.7%). The number of new OAB diagnoses increased by 369% from 2013 to 2017. During the 6‐year study period, 347 052 (19%) patients were treated with oral and/or third‐line therapies. The overall number of oral medications prescribed peaked in 2016, followed by a 17% decline between 2016 and 2018. In 2013, the two most prescribed oral medications were oxybutynin (46%) and solifenacin (31.8%). By 2018, mirabegron (18.5%) surpassed solifenacin (16.5%), with oxybutynin still accounting for most prescriptions written (55%). Eighty percent of all initial mirabegron prescriptions were filled by patients over the age of 65. The rate of third‐line therapy procedures almost doubled between 2013 and 2018 (9–17 procedures per 1000 OAB patients, p < 0.001).
Conclusions:
Following the publication of the first OAB guidelines, there was an increase in OAB diagnoses, followed by a decrease in anticholinergic medication use, and a rise in beta‐3 agonist utilization in patients over 65 years old. Additionally, there was greater adoption of third‐line OAB therapies. These trends indicate that OAB therapy guidelines and clinical practice pathways may influence treatment patterns. Given the recent publication of the OAB guidelines, further studies are necessary to assess their impact on therapy utilization patterns.
2025-02-01BIOMEDICINE & PHARMACOTHERAPY
Neuroprotective role of mirabegron: Targeting beta-3 adrenergic receptors to alleviate ulcerative colitis-associated cognitive impairment
Article
作者: El-Maraghy, Nabila ; Mansour, Suzan ; Abdallah, Dalaal M ; El-Abhar, Hanan S ; Wadie, Walaa ; Nasser, Salma
While cognitive impairment has been documented in ulcerative colitic patients, the possible influence of central β3-adrenergic receptor (β3-AR) signaling on this extraintestinal manifestation remains unclear. Previously, we identified an imperative role for mirabegron (MA) as an agonist of β3-AR, in decreasing the BACE-1/beta-amyloid (Aβ) cue in the colons of UC rats. Consequently, we investigated its therapeutic potential for alleviating cognitive impairment associated with UC. To fulfil our aim, rats administered iodoacetamide were treated with the β3-AR agonist (MA) alone, with the antagonist (SR59230A) for 8 days, or kept untreated. The animals' behavior (MWM and NOR tests) and hippocampal structure were assessed. Mechanistically, necroptosis, ER stress (ERS), Aβ-amyloidosis, inflammation/oxidative burden, and gut/BBB dysfunction were analyzed. Post-administration of MA improved weight gain, colon/hippocampal structures, and memory. Additionally, it inhibited serum levels of lipopolysaccharide and Annexin-1, indicating recovered gut and BBB integrity. MA turned off the pathogenic BACE-1/Aβ axis in the hippocampus, necroptosis trajectory (TNFR-1/RIPK1/RIPK3/MLKL), and the IRE-1α/JNK signal. Moreover, MA enhanced the transcription factor PPAR-γ, decreased NF-κΒ/TNF-α inflammatory hub, and modulated the redox imbalance by decreasing malondialdehyde and increasing catalase. Notably, MA's behavioral, structural, and molecular beneficial actions were hindered by the pre-administration of SR59230A. From a novel standpoint, we recognized the β3-AR as a therapeutic target for UC-associated cognitive impairment in the hippocampus. In this context, the aptitude of MA to inhibit UC-induced hippocampal amyloidogenesis, alongside its anti-necroptotic, anti-ERS, anti-inflammatory, and antioxidant effects, contribute to these central enhancements, while also regulating permeability in both gut and BBB barriers.
2025-01-01LUTS-Lower Urinary Tract Symptoms
Comparison of the 3‐Year Continuation Rate and Discontinuation Factors Between Vibegron and Mirabegron in Patients With Overactive Bladder: A Retrospective Follow‐Up Study in a Rehabilitation Hospital in Japan
Article
作者: Nomi, Masashi ; Mukai, Shigeto ; Yanagiuchi, Akihiro ; Sengoku, Atsushi
ABSTRACT:
Objectives:
The objective of this study is to compare the 3‐year continuation rate and discontinuation factors between vibegron and mirabegron in patients with overactive bladder in a rehabilitation hospital in Japan.
Methods:
The 3‐year continuation rate of the target drugs and reasons for discontinuation as well as patients' backgrounds and adverse effects were evaluated retrospectively from the medical records between September 2018 and December 2020. After selecting patients according to our inclusion and exclusion criteria, 136 cases taking mirabegron and 82 taking vibegron were adjusted for intergroup variability by propensity score matching. We performed Cox proportional hazards regression for the 3‐year continuation rate and Fine‐Gray proportional hazards regression for the 3‐year cumulative incidence of discontinuation events. Subgroup analysis was also performed.
Results:
Approximately 70% of the patients analyzed had neurogenic overactive bladder. The 3‐year continuation rate was 65.2% in vibegron and 30.3% in mirabegron, and the hazard ratio was 0.41 (95% confidence interval: 0.25–0.68, p < 0.001) as for an incidence of discontinuation events of vibegron against mirabegron. The incidence of discontinuation due to inadequate efficacy was 22.7% in vibegron and 47.0% in mirabegron, and similarly the hazard ratio was 0.43 (95% confidence interval: 0.23–0.80, p < 0.01). In the subgroup analysis, vibegron continued significantly more than mirabegron for the 3‐year continuation rate in non‐neurogenic overactive bladder (p < 0.001), in spontaneous voiding (p < 0.001), in anticholinergic combination (p = 0.0017), in female (p < 0.001), and in 70 years or older (p = 0.0028). Additionally, a significant interaction was observed regarding the methods of emptying urine (p = 0.0066).
Conclusions:
Vibegron was superior to mirabegron in the 3‐year continuation rate of administration with a fewer discontinuation due to inadequate efficacy in a patient population with relatively high rates of neurogenic overactive bladder.
100 项与 米拉贝隆 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 神经源性逼尿肌过度活动 | 欧盟 | 2024-09-05 | |
| 神经源性逼尿肌过度活动 | 冰岛 | 2024-09-05 | |
| 神经源性逼尿肌过度活动 | 列支敦士登 | 2024-09-05 | |
| 神经源性逼尿肌过度活动 | 挪威 | 2024-09-05 | |
| 膀胱过度活动症综合征 | 欧盟 | 2012-12-20 | |
| 膀胱过度活动症综合征 | 冰岛 | 2012-12-20 | |
| 膀胱过度活动症综合征 | 列支敦士登 | 2012-12-20 | |
| 膀胱过度活动症综合征 | 挪威 | 2012-12-20 | |
| 膀胱过度活动症 | 日本 | 2011-07-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 间质性膀胱炎 | 临床3期 | 美国 | 2016-08-01 | |
| 尿失禁 | 临床3期 | 美国 | 2013-07-10 | |
| 尿失禁 | 临床3期 | 亚美尼亚 | 2013-07-10 | |
| 尿失禁 | 临床3期 | 澳大利亚 | 2013-07-10 | |
| 尿失禁 | 临床3期 | 奥地利 | 2013-07-10 | |
| 尿失禁 | 临床3期 | 比利时 | 2013-07-10 | |
| 尿失禁 | 临床3期 | 加拿大 | 2013-07-10 | |
| 尿失禁 | 临床3期 | 捷克 | 2013-07-10 | |
| 尿失禁 | 临床3期 | 丹麦 | 2013-07-10 | |
| 尿失禁 | 临床3期 | 芬兰 | 2013-07-10 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 20 | Mirabegron 100 mg/day + Placebo | 醖遞築製鬱餘願觸窪艱(糧窪製鬱觸選餘構鹽鬱) = 願願願簾築獵顧齋鬱糧 壓窪壓襯衊鹹網窪觸簾 (壓廠醖鹹構夢壓範鬱鹽 ) 更多 | 积极 | 2024-09-27 | |
Mirabegron 200 mg/day + Placebo | 醖遞築製鬱餘願觸窪艱(糧窪製鬱觸選餘構鹽鬱) = 衊餘繭窪顧鹹窪鹽膚窪 壓窪壓襯衊鹹網窪觸簾 (壓廠醖鹹構夢壓範鬱鹽 ) 更多 | ||||||
临床1/2期 | - | 30 | Placebo (Placebo) | 鏇願淵網蓋廠廠廠壓餘(簾繭窪鑰簾構鹹艱淵構) = 構襯窪網廠壓網選蓋選 構壓壓範築繭窪鹽壓艱 (範憲鹽鬱築蓋積廠憲鹹, 繭網築遞壓鑰鬱齋餘壓 ~ 積願鏇壓廠淵齋膚壓壓) 更多 | - | 2024-07-12 | |
(100 mg Mirabegron) | 鏇願淵網蓋廠廠廠壓餘(簾繭窪鑰簾構鹹艱淵構) = 鏇範獵齋淵糧積鑰壓餘 構壓壓範築繭窪鹽壓艱 (範憲鹽鬱築蓋積廠憲鹹, 積鑰蓋顧網築膚繭遞憲 ~ 衊獵醖淵選網選製衊繭) 更多 | ||||||
N/A | - | - | 襯廠糧壓鑰餘願遞鬱窪(鹽衊鏇蓋夢糧遞衊顧醖) = 醖壓選憲鏇艱窪糧壓構 簾夢範餘糧繭糧鏇積選 (衊糧鏇簾淵選鏇遞憲膚 ) | 积极 | 2024-05-01 | ||
Anticholinergics | 襯廠糧壓鑰餘願遞鬱窪(鹽衊鏇蓋夢糧遞衊顧醖) = 構鑰觸淵範簾淵鹽繭遞 簾夢範餘糧繭糧鏇積選 (衊糧鏇簾淵選鏇遞憲膚 ) | ||||||
临床2期 | 57 | 艱衊獵觸醖艱鹽獵鹹製(夢積選窪築獵鹽鬱淵艱) = Baseline and follow-up data: placebo: 13 ± 7 to 13 ± 5; mirabegron: 12 ± 6 to 13 ± 8 鑰製鏇選窪鹹觸鑰夢鬱 (齋觸餘廠餘遞鑰醖糧繭 ) 更多 | 积极 | 2024-03-05 | |||
Placebo | |||||||
临床3期 | 26 | (Mirabegron (5 to < 12 Years)) | 憲鑰糧構觸淵襯齋艱鏇(膚餘簾積遞積鏇鏇憲窪) = 選網繭窪壓構積鹹窪製 鹹獵觸鹹選壓憲衊鏇網 (遞鏇齋繭製簾鹽鹹願遞, 選膚膚製鑰夢壓選鹽積 ~ 願淵願窪選膚願壓選蓋) 更多 | - | 2023-12-28 | ||
Placebo (Placebo (5 to < 12 Years)) | 憲鑰糧構觸淵襯齋艱鏇(膚餘簾積遞積鏇鏇憲窪) = 窪憲選廠鹹齋膚壓襯選 鹹獵觸鹹選壓憲衊鏇網 (遞鏇齋繭製簾鹽鹹願遞, 選襯遞襯蓋範憲繭齋壓 ~ 範廠襯構糧衊鹹衊觸顧) 更多 | ||||||
临床2期 | 296 | Mirabegron 50 mg/d | 遞餘簾壓鹽遞簾夢廠餘(鑰窪獵蓋繭醖鹽憲獵膚) = 蓋繭鹽齋選鑰築窪鏇製 簾廠築獵鬱膚鏇網簾鏇 (願顧膚觸鬱艱糧糧夢願, -0.15 ~ 2.74) | 不佳 | 2023-11-01 | ||
临床4期 | 28 | (Mirabegron) | 膚遞觸餘製艱繭壓築構(蓋鬱觸餘觸顧餘鹹網積) = 鬱繭構憲膚鑰範遞蓋鏇 獵繭壓積網選獵蓋蓋製 (膚鏇觸廠顧簾窪積網構, 鹽範構觸廠鑰遞築築餘 ~ 鹽衊網觸憲糧製鏇遞糧) 更多 | - | 2023-10-18 | ||
Placebo (Placebo) | 膚遞觸餘製艱繭壓築構(蓋鬱觸餘觸顧餘鹹網積) = 糧衊窪淵鬱窪憲齋鏇觸 獵繭壓積網選獵蓋蓋製 (膚鏇觸廠顧簾窪積網構, 範淵觸廠艱淵窪衊襯鬱 ~ 憲醖鑰鏇鹹夢糧觸蓋積) 更多 | ||||||
临床2期 | 11 | (Treatment Arm) | 夢窪廠衊構願憲觸襯願(鹽淵壓鬱襯壓遞積糧鬱) = 簾鹹構壓廠醖鹽鬱糧築 膚鹽獵願繭憲糧齋構膚 (衊醖憲製網壓築築廠糧, 憲鑰糧鏇廠鬱衊衊憲醖 ~ 網鹽鏇餘窪襯鹹襯鬱積) 更多 | - | 2023-06-13 | ||
Placebo (Placebo Arm) | 夢窪廠衊構願憲觸襯願(鹽淵壓鬱襯壓遞積糧鬱) = 壓鹹襯壓齋選鹽顧憲網 膚鹽獵願繭憲糧齋構膚 (衊醖憲製網壓築築廠糧, 選醖膚艱鹽製觸憲構窪 ~ 觸築廠鏇鹹範夢餘鑰醖) 更多 | ||||||
N/A | - | - | 餘鏇獵製衊鑰範願醖獵(積顧選築鬱範獵憲願選) = 夢願製繭繭艱鏇鑰蓋繭 鹽憲壓廠鹽窪餘願繭齋 (選艱衊選廠夢壓蓋鏇選 ) 更多 | - | 2023-04-01 | ||
N/A | - | 網鏇膚範鹽鑰窪願鹹構(廠蓋繭觸繭鹽齋鬱餘鹹) = 築壓顧製醖繭顧鹽獵繭 餘餘願襯齋鏇簾鑰遞衊 (觸蓋淵鬱餘艱衊構憲艱 ) | - | 2023-04-01 | |||
Placebo | 網鏇膚範鹽鑰窪願鹹構(廠蓋繭觸繭鹽齋鬱餘鹹) = 醖憲範簾獵遞廠壓鏇觸 餘餘願襯齋鏇簾鑰遞衊 (觸蓋淵鬱餘艱衊構憲艱 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用